Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Corcept Therapeutics (CORT)

Corcept Therapeutics (CORT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,662,646
  • Shares Outstanding, K 105,188
  • Annual Sales, $ 675,040 K
  • Annual Income, $ 141,210 K
  • EBIT $ 66 M
  • EBITDA $ 56 M
  • 60-Month Beta 0.25
  • Price/Sales 5.63
  • Price/Cash Flow 27.57
  • Price/Book 5.70

Options Overview Details

View History
  • Implied Volatility 69.32% (-5.72%)
  • Historical Volatility 80.15%
  • IV Percentile 49%
  • IV Rank 31.90%
  • IV High 138.94% on 12/15/25
  • IV Low 36.71% on 08/28/25
  • Expected Move (DTE 26) 4.57 (13.13%)
  • Put/Call Vol Ratio 3.70
  • Today's Volume 3,719
  • Volume Avg (30-Day) 3,352
  • Put/Call OI Ratio 1.51
  • Today's Open Interest 60,157
  • Open Int (30-Day) 46,072
  • Expected Range 30.25 to 39.39

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.27
  • Number of Estimates 4
  • High Estimate 0.30
  • Low Estimate 0.18
  • Prior Year 0.26
  • Growth Rate Est. (year over year) +3.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
28.66 +21.49%
on 02/19/26
47.06 -26.01%
on 01/28/26
-0.47 (-1.33%)
since 01/20/26
3-Month
28.66 +21.49%
on 02/19/26
89.00 -60.88%
on 12/15/25
-40.23 (-53.60%)
since 11/20/25
52-Week
28.66 +21.49%
on 02/19/26
117.33 -70.32%
on 03/31/25
-30.27 (-46.50%)
since 02/20/25

Most Recent Stories

More News
Investor Alert: Robbins LLP Informs Investors of the Corcept Therapeutics Inc. Class Action Lawsuit

Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Corcept Therapeutics Incorporation (NASDAQ: CORT) common stock between...

CORT : 34.82 (+1.69%)
Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic...

CORT : 34.82 (+1.69%)
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results, Provide Corporate Update and Host Conference Call

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2025 financial results and provide a corporate update on February 24, 2026. The company will...

CORT : 34.82 (+1.69%)
3 Small-Cap Stocks We Think Twice About

3 Small-Cap Stocks We Think Twice About

CORT : 34.82 (+1.69%)
RELL : 13.68 (+4.35%)
EPC : 22.72 (+2.48%)
CORT ALERT: Ongoing Investigation Into Corcept Therapeutics Incorporated - Contact Levi & Korsinsky

New York, New York--(Newsfile Corp. - February 16, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Corcept Therapeutics Incorporated ("Corcept Therapeutics Incorporated")...

CORT : 34.82 (+1.69%)
3 Cash-Producing Stocks We’re Skeptical Of

3 Cash-Producing Stocks We’re Skeptical Of

CORT : 34.82 (+1.69%)
RH : 207.73 (+1.51%)
SMTC : 86.77 (+2.13%)
Inspire Medical Systems, Astrana Health, Evolent Health, Corcept, and Centene Stocks Trade Up, What You Need To Know

Inspire Medical Systems, Astrana Health, Evolent Health, Corcept, and Centene Stocks Trade Up, What You Need To Know

INSP : 59.53 (-0.42%)
CORT : 34.82 (+1.69%)
EVH : 2.79 (+0.72%)
ASTH : 19.86 (+0.46%)
CNC : 43.24 (-1.01%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT

NEW YORK , Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT).  Such investors...

CORT : 34.82 (+1.69%)
CORT INVESTIGATION ALERT: Investigation Launched into Corcept Therapeutics (CORT), Hagens Berman Encourages Investors to Contact Firm

SAN FRANCISCO , Feb. 9, 2026 /PRNewswire/ -- The latest adverse development for Corcept Therapeutics (NASDAQ: CORT) concerning its proposed treatment of patients with hypercortisolism (also known...

CORT : 34.82 (+1.69%)
Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights - CORT

LOS ANGELES , Feb. 9, 2026 /PRNewswire/ --  The DJS Law Group  announces that it is investigating claims on behalf of investors of Corcept Therapeutics Incorporated ("Corcept" or "the Company")...

CORT : 34.82 (+1.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Corcept is focused on the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncology disorders which are associated with the activity of the hormone cortisol, also known as the stress hormone. Corcept's only marketed drug, Korlym (mifepristone),...

See More

Key Turning Points

3rd Resistance Point 37.25
2nd Resistance Point 36.16
1st Resistance Point 35.49
Last Price 34.82
1st Support Level 33.72
2nd Support Level 32.62
3rd Support Level 31.95

See More

52-Week High 117.33
Fibonacci 61.8% 83.46
Fibonacci 50% 73.00
Fibonacci 38.2% 62.53
Last Price 34.82
52-Week Low 28.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar